Overbeck, Tobias R.

[["dc.bibliographiccitation.firstpage","179"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Dermatology"],["dc.bibliographiccitation.lastpage","182"],["dc.bibliographiccitation.volume","225"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T09:14:44Z"],["dc.date.available","2018-11-07T09:14:44Z"],["dc.date.issued","2012"],["dc.description.abstract","Erlotinib inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR) and is successfully used in lung cancer treatment. EGFR is essential in skin development and function and may have a role in the pathogenesis of psoriasis. Cutaneous side effects are very common in patients treated with erlotinib, and therapeutic use of erlotinib in dermatological disorders has therefore not been considered. We report two cases of patients with lung cancer and concomitant psoriasis treated with erlotinib with complete resolution of the skin problems. We present a review of the current literature on the topic. Copyright (C) 2012 S. Karger AG, Basel"],["dc.description.sponsorship","Roche"],["dc.identifier.doi","10.1159/000342786"],["dc.identifier.isi","000311760700015"],["dc.identifier.pmid","23095682"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27489"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1018-8665"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Lung Cancer"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schondube, F."],["dc.contributor.author","Schmidtberger, H."],["dc.contributor.author","Andreas, S."],["dc.contributor.author","Schirren, J."],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Keppler, U."],["dc.contributor.author","Leupold, H."],["dc.contributor.author","Baum, R."],["dc.date.accessioned","2018-11-07T09:26:18Z"],["dc.date.available","2018-11-07T09:26:18Z"],["dc.date.issued","2005"],["dc.format.extent","S26"],["dc.identifier.doi","10.1016/S0169-5002(05)80201-6"],["dc.identifier.isi","000231307800076"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30268"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.publisher.place","Clare"],["dc.relation.conference","11th World Conference on Lung Cancer"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","0169-5002"],["dc.title","Phase II induction therapy with docetaxel and carboplatin in NSCLC IIIA/IIIB: FDG-PET response predicts overall and disease free survival"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Serke, Monika Heidi"],["dc.contributor.author","Grohe, Christian"],["dc.contributor.author","Hillejan, Lars"],["dc.contributor.author","Passlick, Bernward"],["dc.contributor.author","Reinmuth, Nils"],["dc.contributor.author","Graeven, Ullrich"],["dc.contributor.author","Lueers, Anne C."],["dc.contributor.author","Radke, Susanne M."],["dc.contributor.author","Karatas, Aysun"],["dc.contributor.author","Tiemann, Markus"],["dc.contributor.author","Heukamp, Lukas"],["dc.contributor.author","Overbeck, Tobias R."],["dc.date.accessioned","2018-11-07T09:51:51Z"],["dc.date.available","2018-11-07T09:51:51Z"],["dc.date.issued","2015"],["dc.format.extent","S564"],["dc.identifier.isi","000370365102534"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35996"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","1556-1380"],["dc.relation.issn","1556-0864"],["dc.title","Induction Therapy with Intercalated TKI and Chemotherapy in NSCLC with Activating EGFR Mutation in Stages II-IIIB: NeoIntercal"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Serke, Monika Heidi"],["dc.contributor.author","Buettner, Reinhardt"],["dc.contributor.author","Waller, C."],["dc.contributor.author","Reinmuth, Nils"],["dc.contributor.author","Graeven, Ullrich"],["dc.contributor.author","Lueers, Anne C."],["dc.contributor.author","Radke, Susanne M."],["dc.contributor.author","Karatas, Aysun"],["dc.contributor.author","Heukamp, Lukas Carl"],["dc.contributor.author","Tiemann, Markus"],["dc.contributor.author","Overbeck, Tobias R."],["dc.date.accessioned","2018-11-07T09:50:37Z"],["dc.date.available","2018-11-07T09:50:37Z"],["dc.date.issued","2015"],["dc.format.extent","140"],["dc.identifier.isi","000364268800331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35741"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: Neolntercal"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","4"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schaeper, Christoph"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Groescheld, Andreas"],["dc.contributor.author","Haug, Alexander"],["dc.contributor.author","Leschber, Gunda"],["dc.contributor.author","Pfluger, Thomas"],["dc.contributor.author","Poettgen, Christoph"],["dc.date.accessioned","2018-11-07T09:20:39Z"],["dc.date.available","2018-11-07T09:20:39Z"],["dc.date.issued","2013"],["dc.identifier.isi","000324083200002"],["dc.identifier.pmid","24162624"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28929"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","0378-584X"],["dc.title","Tumor Conference I"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2096"],["dc.bibliographiccitation.issue","41"],["dc.bibliographiccitation.journal","DMW - Deutsche Medizinische Wochenschrift"],["dc.bibliographiccitation.lastpage","2100"],["dc.bibliographiccitation.volume","139"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Niederle, N."],["dc.contributor.author","Thomas, M."],["dc.contributor.author","Reck, Martin"],["dc.contributor.author","Schmittel, A."],["dc.contributor.author","Fischer, B."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Groeschel, Andreas"],["dc.contributor.author","Deppermann, M."],["dc.contributor.author","Pirker, R."],["dc.contributor.author","Huber, R. M."],["dc.contributor.author","Eberhardt, W."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T09:34:31Z"],["dc.date.available","2018-11-07T09:34:31Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1055/s-0034-1387294"],["dc.identifier.isi","000342982400011"],["dc.identifier.pmid","25268213"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32185"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1439-4413"],["dc.relation.issn","0012-0472"],["dc.title","Molecular genetic tests in advanced non-small cell lung cancer: practical relevance"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","British Journal of Cancer"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T10:34:16Z"],["dc.date.available","2018-11-07T10:34:16Z"],["dc.date.issued","2003"],["dc.format.extent","S31"],["dc.identifier.isi","000188229500035"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44821"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.publisher.place","London"],["dc.relation.conference","Iressa Clinical Experience (ICE) Meeting"],["dc.relation.eventlocation","MADRID, SPAIN"],["dc.relation.issn","0007-0920"],["dc.title","Response and symptom improvement with gefitinib ('Iressa', ZD1839) 250 mg day(-1) in a patient with poor performance status"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Dorge, H."],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Andreas, S."],["dc.contributor.author","Keppler, U."],["dc.contributor.author","Schirren, J."],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Baum, R. P."],["dc.date.accessioned","2018-11-07T10:47:47Z"],["dc.date.available","2018-11-07T10:47:47Z"],["dc.date.issued","2005"],["dc.format.extent","666S"],["dc.identifier.isi","000230326604300"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48045"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","41st Annual Meeting of the American-Society-of-Clinical-Oncology"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Phase II induction therapy with docetaxel and carboplatin in NSCLC llIAAIlB: FDG-PET response predicts overall and disease free survival."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]